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Abstract
Background: Amitraz is a pesticide used worldwide on animals and in agriculture. It contains triazapentadiene,
which is a centrally acting alpha-2 adrenergic agonist. Amitraz poisoning is fairly uncommon in humans and
occurs via oral, dermal or inhalational routes. Only a limited number of case reports of human intoxication have
been published and most of them are of accidental ingestion by children.
Case presentation: A twenty-year-old Sri Lankan female presented following self-ingestion of 20 ml of amitraz
resulting in 37.8 mg/ kg of amitraz poisoning. She lost consciousness after 20 min of ingestion, developed
bradycardia and hypotension, which needed intravenous fluid resuscitation and dobutamine. Gastric lavage
was performed. Her bradycardia persisted for 36 h and she was drowsy for 48 h. She did not develop respiratory
depression, convulsions or hypothermia and the urine output was normal. Arterial blood gas revealed mild
respiratory alkalosis. She recovered fully within 48 h and was discharged on day 3.
Conclusion: The clinical manifestations of amitraz (impaired consciousness, drowsiness, vomiting, disorientation,
miosis, mydriasis, hypotension, bradycardia, respiratory depression, hypothermia, generalized seizures, hyperglycemia
and glycosuria) can be explained by the agonist action of amitraz on α1 and α2 receptors. Management of amitraz
poisoning is still considered to be supportive and symptomatic with monitoring of nervous system, cardiovascular
and respiratory systems. Activated charcoal may still be considered for treatment and the place for gastric lavage is
controversial. Atropine is effective for symptomatic bradycardia and inotropic support is needed for hypotension that
does not respond to fluid resuscitation. Diazepam or Lorazepam is used for convulsions and some patients may require
intubation and ICU care. Several α2 adrenergic antagonists like yohimbine have been tried on animals, which have
successfully reversed the effects of amitraz. Since the majority of amitraz poisoning cases are due to accidental
ingestion, manufactures, regulatory authorities and national poisons control centers have a significant role to play in
minimizing its occurrence.
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Background
Amitraz is a pesticide used worldwide on both ani-
mals and crops. It is used to control pests including
generalized demodicosis in canines, ticks and mites in
cattle and sheep, psylla infection in pears and also
red spider mites in fruit crops [1, 2]. It contains tria-
zapentadiene [1,5 di- (2,4-dimethylphenyl)-3-methyl-1,
3,5-tri-azapenta- 1,4 diene] [3]; an insecticide from
the formamadine family. Commercially available for-
mulations generally contain 12.5–20% of the com-
pound in organic solvents [4].
When humans are exposed to amitraz, the clinical
manifestations varies from central nervous system (CNS)
depression (drowsiness, coma, and convulsions), miosis
or mydriasis, respiratory depression, cardiovascular depres-
sion (bradycardia, hypotension), hypothermia or hyperther-
mia, hyperglycemia, polyuria, vomiting and decreased
gastrointestinal motility. These manifestations can be* Correspondence: tharukaherath11@gmail.com
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explained by its alpha-adrenergic agonist action, which is
on central alpha-2 adrenergic receptors as well as periph-
eral α2 and α1 receptors.
Amitraz poisoning is fairly uncommon in humans and
occurs via oral, dermal or inhalational routes [1, 2, 5–7].
Oral route is the most common giving rise to more se-
vere manifestations [8, 9]. Here we report a young fe-
male who presented following self-ingestion of amitraz
and developed central nervous system (CNS) and cardio-
vascular manifestations. She ingested of 20 ml of amitraz
(From 2 ml to 50 ml of amitraz poisoning cases are re-
ported in literature) resulting in a concentration of
37.8 mg/kg (The minimum toxic dose reported was
3.57 mg/kg) and recovered fully after 2 days. In this pa-
tient, nervous system depression developed quite rapidly
(within 20 min) followed by cardiovascular depression
requiring inotropic support.
Only a limited number of case reports of human in-
toxication have been published and most of them are of
accidental ingestion by children [1, 3, 6, 7, 9–14]. Case
reports on amitraz poisoning in Asian adults are rarer
and we could only find a few cases reported in Southeast
Asia so far even after an extensive literature survey. So
the general awareness regarding the management of this
toxin among clinicians is lacking in Asian countries.
Here we review the case reports published up to now in
reference to effects of amitraz, possible mechanisms of
its action and the treatment options including those at
experimental level. All the cases reported so far, have
been managed with supportive measures with regards to
nervous system and cardiovascular depression. Though
several alpha2 adrenergic antagonists have been tried on
animals to reverse the effects of amitraz with success,
still no specific antidote has been tried on humans
leaving only the previous case reports and case series to
aid physicians in therapy. Importance of taking serious
precautions against this compound is also emphasized,
as accidental ingestion is the commonest mode of
presentation.
Case presentation
A twenty-year-old Sri Lankan female presented following
self-ingestion of 20 ml of amitraz (12.5 W/V) following a
family dispute leading to the compulsive act. She was
66 kg in weight and 144 cm in height, resulting in
37.8 mg/ kg of amitraz poisoning. She recalled being
alert for about 20 min following ingestion and was found
unconscious by her parents. Four hours following inges-
tion, on admission to the hospital, her Glasgow coma
scale (GCS) was 10/15. Pupils were equal and 3 mm in
size. Deep tendon reflexes were normal. She had brady-
cardia with a heart rate of 55 beats per minute,
hypotension with a blood pressure of 80/60 mmHg and
a respiratory rate of 18 cycles per minute. Gastric lavage
was performed along with intravenous fluid boluses.
Intravenous dopamine 5 μg/kg/min was given for four
hours to maintain blood pressure. Her bradycardia per-
sisted for 36 h and she was drowsy for 48 h. She had
nausea but not vomiting and did not open her bowels
for 3 days. However the bowel sounds were normal. She
did not develop respiratory depression, convulsions or
hypothermia and the urine output was normal.
ECG revealed sinus bradycardia with a normal QT
duration and the blood sugar was normal throughout.
Full blood count, liver function tests, Urine full re-
port, serum creatinine and electrolytes were normal
(Table 1). Arterial blood gases revealed mild respira-
tory alkalosis with a pH of 7.47, pCO2 of 30 mmHg
and a HCO3− of 21.6 mmol/L. There was no hypoxia.
She recovered fully within 48 h and was discharged
on day 3.
Discussion
Amitraz is an alpha2 adrenergic receptor agonist. It
stimulates α2 receptors in the CNS, α2 and α1 receptors
in the periphery [15] and also inhibits monoamine oxi-
dase (MAO) enzyme activity and prostaglandin E2 syn-
thesis [3, 16, 17]. The effects of amitraz in animals
resemble that of pure alpha 2-adrenergic agonist drugs
like clonidine [3, 4, 12, 18]. It can also be misdiagnosed
as organophosphate or carbamate toxicity, since all three
share several similar clinical features [19]. Opioids, bar-
biturates, benzodiazepines, phenothiazines and tricyclic
antidepressants can also display similar symptoms and
signs in overdose. Its acute oral median lethal dose
(LD50) for rats is 523-800 mg/kg body weight and >
1600 mg/kg in mice [1, 3]. Two human deaths have been
reported following ingestion of amitraz and one had
ingested 6 g [1, 17] of the compound. The minimum
toxic dose reported by Jorens P. G. et al. is 3.57 mg/kg
[3]. Our patient had ingested 2500 mg orally (37.8 mg/
kg). The clinical manifestations of poisoning include
CNS depression, respiratory depression and cardiovascu-
lar effects.
In most case reports the onset of action ranged be-
tween 30-180 min following ingestion [1, 6]. In a case
series by Yaramis, A. et al., CNS depression had been
observed within 30–90 min and resolved within 8 ½ to
14 h [10]. Aydin, K. et al., had described CNS depression
in 8 children occurring within 30–120 min and resolving
after 8–18 h [7]. Kalyoncu however had reported a more
rapid and wider range of onset of action; five minutes to
six hours for the oral route and five minutes to twenty
four hours [8] for dermal exposure. Our patient had lost
her consciousness 20 min after ingestion, which was
comparatively rapid. In almost all cases, patients fully re-
covered within 48 h and were discharged. Our patient
also recovered within 48 h.
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As in our patient, drowsiness was the predominant
manifestation observed in cases of amitraz poisoning [1,
2, 5–7, 9, 10, 20, 21] and is probably due to the alpha 2
agonist action. In a case series by Yilmaz, H. L., impaired
consciousness was predominant with drowsiness, dis-
orientation and a median pediatric Glasgow coma scale
of 9 [1]. In this study three patients had short general-
ized seizures and Ertekin, V. et al., also reported general-
ized seizures following Amitraz poisoning [6]. In all the
cases seizures responded to diazepam. Deep coma [18,
20] and vomiting [2, 5, 6, 18, 22] were also described.
Ataxia, stupor, and coma were attributable to the xylene
and propylene oxide components in amitraz [4]. Shitole,
D. G. et al., had reported cerebral edema in the CT brain
of a patient who was found unconscious following Ami-
traz poisoning [22]. In animal studies, CNS stimulation
has been described at low doses, which manifested as
hyperactivity to external stimuli [23]. However, this has
not been reported in humans. Miosis with absence of
light reflex is also commonly seen [1, 5, 10, 19–21, 24].
Mydriasis has also been described but less commonly [1,
5, 9, 22, 24, 25]. This is because at low doses, α2 adren-
ergic agonists induce miosis by its effect on presynaptic
receptors and in higher doses cause mydriasis by its ac-
tion on postsynaptic receptors [26, 27]. In our patient,
the pupil size was normal.
The α1 and α2 agonistic action of amitraz causes
bradycardia and hypotension [3] which were seen in sev-
eral case reports [1, 2, 5, 6, 10, 18–21, 24]. Some needed
intravenous fluid for resuscitation [22, 28] and some pa-
tients were treated with atropine for bradycardia and
hypotension [1, 9, 10, 12, 28]. In a few cases dopamine
was also given as a second line inotrope [24]. Aydin, K.
et al., in his study had reported nonspecific ST changes
in the ECG of seven children which had resolved com-
pletely [12]. QT prolongation was seen in an English
bulldog with amitraz toxicity [29]. In our patient the
ECG showed sinus bradycardia only.
Respiratory depression is also common [7, 10] and
severe respiratory depression had required mechanical
ventilation in some cases [1, 2, 5, 7, 9, 11, 18]. No abnor-
mality has been reported in the blood gasses of majority
of the cases [1]. However Kalyoncu and colleagues had
reported respiratory alkalosis in two cases, respiratory
acidosis in three cases, and metabolic acidosis in five
cases [8]. Mild respiratory alkalosis was seen in the ar-
terial blood gas analysis of our patient. Aspiration pneu-
monitis because of emesis is also reported [9].
As in our patient, the levels of blood urea nitrogen,
creatinine, serum sodium and potassium are usually
within normal range in most cases [1]. However hyper-
natremia has been rarely reported [8, 20]. Minimal in-
creases in the level of serum ALT and AST were also
reported rarely and all had recovered within a few days
[1, 5–7, 12, 24]. Mean AST elevation was higher than
mean ALT elevation in one study [5]. Ertekin and his
colleagues had detected elevated alkaline phosphatase
levels in a few cases [6]. However, available evidence
does not indicate any significant alteration of liver func-
tions, renal functions or hematological parameters with
amitraz poisoning. The significance of the reported mild
alterations is yet to be determined.
Abu-Basha and colleagues had demonstrated that ami-
traz, along with its active metabolite BTS 27271, acts on
alpha2D-adrenergic receptors in pancreatic islets of rats
inhibiting insulin and stimulating glucagon secretion
[30]. High Blood glucose with glycosuria was also re-
ported in human poisoning as well [1, 5, 6]. Decreased
body temperature was seen in several cases [1, 2, 6, 24]
and only Ulukaya, S. et al., had reported hyperthermia
[24]. Hugnet and colleagues had shown that hypothermia
could be related to the α2 agonist activity of amitraz by ad-
ministering it to dogs [31]. Amitraz has been shown to in-
hibit prostaglandin E2 synthesis [3, 11, 16, 32], which can
explain the antipyretic and anti-inflammatory activity
in vivo. Increased urine output was described in four cases
by Yilmaz, H. L [1] and was also seen in dogs [31]. It is
postulated to be due to α2 adrenoceptor stimulation caus-
ing decreased antidiuretic hormone (ADH) and renin se-
cretion [26]. α2 adrenoceptor stimulation by amitraz has
Table 1 Full blood count, liver function tests, and serum electrolytes
Investigation and value Normal range Comment Investigation and value Normal range Comment
WBC 9.32 × 103/μL 4–10 Normal Neutrophils 6.09× 103/μL 2–7 Normal
Lymphocytes 2.17 × 103/μL 0.8–4 Normal Platelets 277 × 103/μL 150–450 Normal
Serum creatinine 0.9 mg/dl 60–120 Normal Serum sodium 138 mmol/L 135–148 Normal
Serum potassium 3.4 mmol/ 3.5–5.1 Normal Normal
AST 27 U/L 10–35 Normal ALT 20 U/L 10–40 Normal
Alkaline phosphatase = 104 U/L 100–360 Normal INR 1.26 Normal
Ionized calcium 1.21 mmol/L (1.0–1.3) Normal Serum magnesium 1.7 mg/dl (1.7–2.7) Normal
Amylase 68 U/L (22–80) Normal Troponin I < 0.1 ng/ml <0.5 Normal
CK-MB < 2 ng/ml < 5 Normal Normal
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been shown to cause hypomotility of the gastrointestinal
tract in dogs [33]. Ogilvie's syndrome characterized by ab-
dominal pain, severe tenderness and distension which re-
covered after neostigmine administration was reported in
a 36-year-old female following amitraz poisoning [34].
There is no specific antidote for amitraz poisoning and
the management is supportive with monitoring and
evaluation of the respiratory, cardiac, and central ner-
vous systems. The role of activated charcoal has not
been studied, and there are no data comparing the ef-
fectiveness gastric lavage and activated charcoal in rela-
tion to amitraz. However it may still be considered for
treatment. In many cases, both gastric lavage and acti-
vated charcoal have been tried [10, 17, 20, 29, 34],
Yilmaz et al. recommend gastric lavage only in massive
doses, to be performed after endotracheal intubation in
order to avoid inhalation or aspiration pneumonitis [1].
Atropine has been used with success in patients who de-
veloped bradycardia [1, 6, 9, 10, 12, 29, 35]. Atropine
sulfate (0.045 mg/kg, iv) had increased the heart rate in
dogs and prevented amitraz-induced bradycardia [35].
Yilmaz H. L. had concluded that using atropine is
effective only when there is symptomatic bradycardia
and asymptomatic bradycardia or miosis did not require
atropine use [1]. For hypotension, intravenous fluid re-
suscitation and inotropic agents (dopamine or noradren-
aline) can be added as needed [1, 10, 13, 24]. Seizures
respond to diazepam and lorazepam [1, 6, 10, 11].
Oxygen should be given if the oxygen saturation drops
and some patients with severe respiratory depression
need intubation and intensive care unit (ICU) stay [1, 2,
5, 7, 9, 11, 18].
Several alpha2 adrenergic antagonists have been tried
on animals to reverse the effects of amitraz. Yohimbine,
an α2-adrenoceptor antagonist, prevented the amitraz in-
duced hyperglycemia [36], CNS depression [37, 38],
gastrointestinal effects, bradycardia [33, 35], sedation, loss
of reflexes, hypothermia, hypotension, bradypnea and my-
driasis [39]. Atipamezole, a new α2 adrenergic antagonist
also prevented the effects of amitraz with less side effects
compared to yohimbine [39]. The nonselective alpha-
adrenoceptor antagonist tolazoline prevented some effects
[37]. α1-adrenoceptor antagonist prazosin did not reverse
the effects of amitraz [36, 37]. The muscarinic receptor
antagonist atropine and the opioid receptor antagonist na-
loxone did not prevent the effects of amitraz on CNS.
With regards to our patient, management was mainly
supportive and symptomatic with initial stabilization, re-
ducing absorption, and monitoring for complications.
Gastric lavage was performed at presentation to the hos-
pital as a gastrointestinal decontamination method. The
American Association of Poison Centers (AAPC) and
the European Association of Poison Centers and Clinical
Toxicologists (EAPCCT) recommend that gastric lavage
should not be employed routinely and to perform only if
the patients present early (within one hour of ingestion)
and if potentially lethal ingestion is present. In our pa-
tient, the amount and the timing of poisoning was not
clear on admission. Therefore after initial stabilization
and excluding contraindications we performed gastric
lavage. Activated charcoal was not given even though it
could have been considered as described earlier. We also
recommend gastric lavage or activated charcoal in pa-
tients with amitraz poisoning only if a large amount is
ingested and if the procedure can be performed within
one hour of ingestion after initial stabilization and air-
way protection.
For hypotension we used intravenous fluid resuscita-
tion along with dopamine. As discussed above dopamine
had been used in a few case reports with success.
Dopamine is a type of catecholamine and has inotropic
and chronotropic effects. At doses of 5-10 μg/kg/min,
dopamine stimulates β1 adrenergic receptors and in-
creases cardiac output, by increasing cardiac contractility
with variable effects on heart rate. Doses between 2–
5 μg/kg/min have variable effects on hemodynamics in
individual patients because vasodilation (by its action on
dopamine-1 receptors) is often balanced by increased
stroke volume, producing little net effect upon systemic
blood pressure. Since only very few case reports on ino-
trope use in amitraz poisoning are available, convincing
data to support any inotrope as the preferred first-line is
lacking. Therefore to counteract the bradycardia and
hypotension caused by amitraz, we suggest dopamine to
be used in doses of 5–10 μg/kg/min as in our patient.
Since amitraz inhibits monoamine oxidase, the dosage
should be as low as possible. So we used a dose of 5 μg/
kg/min. We did not use atropine as the patient did not
have symptomatic bradycardia and the heart rate was
stable above 50 beats/min.
Conclusion
Majority of amitraz poisoning occurs due to accidental in-
gestion by children. Here we present a young female with
37.8 mg/ kg of amitraz poisoning who developed CNS de-
pression, bradycardia and hypotension requiring inotrope
support. The effects lasted for 48 h. The clinical manifes-
tations of amitraz (impaired consciousness, drowsiness,
vomiting, disorientation, miosis, mydriasis, hypotension,
bradycardia, respiratory depression, hypothermia, general-
ized seizures, hyperglycemia and glycosuria) can be ex-
plained by the agonist action of amitraz on α1 and α2
receptors. Drowsiness is the predominant manifestation
whereas seizures and deep coma is also reported.
Bradycardia and hypotension are the cardiovascular
manifestations and respiratory depression too is com-
mon. Liver biochemistry, renal biochemistry, serum
electrolyte and blood gases are rarely effected.
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Management of amitraz poisoning is still considered
to be supportive and symptomatic with monitoring of
nervous system, cardiovascular and respiratory systems.
The place for gastric lavage and activated charcoal is
controversial but may still be considered for treatment.
Atropine is effective for symptomatic bradycardia and
inotropic support might be needed for hypotension des-
pite adequate fluid resuscitation. Diazepam or Loraze-
pam is generally effective for convulsions although some
patients needed intubation and ICU care. Despite a life
threatening clinical picture with nervous system and car-
diovascular depression, recovery usually occurred within
12–48 h in reported cases of amitraz poisoning in
humans and the patients were discharged without any
organ dysfunction. Several α2 adrenergic antagonists like
yohimbine have been tried on animals that successfully
reversed the effects of amitraz. However, since no stud-
ies or isolated reports have reported the use of these an-
tagonists in humans, they may only be considered in
severe or non-responsive cases. Manufactures, regulatory
authorities and national poisons control centers have a
significant preventive role to play considering the fact
that accidental ingestion is the commonest reported
mode of Amitraz poisoning.
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